Oncology
Pembrolizumab Gains Traditional Approval in TMB-High Tumors
The FDA action covers adults and children with unresectable or metastatic solid tumors measuring at least 13 mutations/Mb after prior progression when satisfactory alternatives are unavailable.
Rayan Salih · November 10, 2026 · 7 min